After validation by a series of follow‐up case–control studies, the plasma‐based SEPT9 gene methylation assay, developed as the “Epi proColon” test, was ultimately approved by the US FDA in 2016 as the only blood‐based CRC screening test (Table 1).66, 84, 95. Here, SEPTIN9 is linked to colorectal carcinoma.